Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CT-3505 in advanced ALK-positive non-small cell lung cancer after failure of second-generation ALK inhibitors
CTR20231352Phase 2Active
- Sponsor
- Shouyao Holdings
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ficonalkib in non-small cell lung cancer (NSCLC), sponsored by Shouyao Holdings. Started Jul 2023; status: active.
02
Drugs
ficonalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20231352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231352.